<?xml version='1.0' encoding='utf-8'?>
<document id="31597901"><sentence text="[Quantitative assessment of the risk of OATP1B1/1B3-mediated drug-drug interactions]." /><sentence text="Drug transporters play important roles in determining drug pharmacokinetics" /><sentence text=" Organic anion transporting polypeptides 1B1/1B3 (OATP1B1/1B3) are transporters mediating hepatic uptake of various anionic drugs" /><sentence text=" OATP1B1/1B3 activities are changed by genetic mutation and drug-drug interaction (DDI) that could lead to severe adverse reactions" /><sentence text=" Methods to address the precise DDI risk assessment have been developed in addition to the translational assessment from the results of in vitro studies" /><sentence text=" Using endogenous substrates as probes is an emerging approach that allows clinical assessment of the DDI risk in the early phase of drug development" /><sentence text=" Then, the clinical data will be subjected to the pharmacokinetic analysis using physiologically-based pharmacokinetic models to perform the more realistic DDI risk assessment with OATP1B1/1B3 substrate drugs" /><sentence text=" When drug targets are located inside the hepatocytes, DDI impact on the intrahepatic concentration is critical for their pharmacological actions" /><sentence text=" Positron emission tomography (PET) allows researchers to determine tissue concentration time profiles of the PET probe upon the inhibition of OATP1B1/1B3, and to estimate the change in kinetic parameter for each intrinsic process of hepatic elimination of PET probe" /><sentence text=" Integration of the clinical data into the PBPK model realizes more precise prediction of DDI impact on the pharmacokinetics of drugs, and their therapeutic effects" /><sentence text="" /></document>